Viking Therapeutics Stock Forecast

Stock Price Forecast

According to 21 analysts polled by S&P Global, Viking Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $95.05. The average 1-year stock price forecast is 292.61% higher than the current stock price, while the lowest is $38 (+56.96%) and the highest is $125 (+416.32%).

Price Target: $95.05 (+292.61%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$38	$95.05	$95	$125
Change	+56.96%	+292.61%	+292.40%	+416.32%

Analyst Ratings

The average analyst rating for Viking Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	13	13	13	13	13	14
Buy	5	5	5	5	5	5
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	20	20	20	20	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward Nash Canaccord Genuity	Canaccord Genuity	Buy Reiterates $114 → $106	Buy	Reiterates	$114 → $106	+337.84%	Oct 20, 2026
Joon Lee UBS	UBS	Buy Initiates $94	Buy	Initiates	$94	+288.27%	Oct 14, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $102	Buy	Reiterates	$102	+321.31%	Oct 14, 2026
Naz Rahman Maxim Group	Maxim Group	Buy Reiterates $70	Buy	Reiterates	$70	+189.14%	Oct 7, 2026
Gregory Renza Truist Financial	Truist Financial	Buy Maintains $87 → $85	Buy	Maintains	$87 → $85	+251.09%	Oct 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-4.59

from -3.19

EPS Next Year

-4.34

from -4.59

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-55.68M	-70.36M	-100.83M	-150.92M	-393.34M	-562.25M
Net Income	-54.99M	-68.87M	-85.90M	-109.96M	-359.64M	-541.57M
EPS	-	-	-	-	-3.19	-4.59
Free Cash Flow	-	-	-	-	-696.72M	-496.50M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.81
Avg	-4.59
Low	-5.35

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-